Re: Dr. Druker Award

[Guest guest]

Lottie, this wasn't very novel, but I did send Dr. Druker a congratulatory

email, from one of his " older " patients.

Bobby

On Thu, May 7, 2009 at 5:27 PM, Lottie Duthu <lotajam@...> wrote:

>

>

> Dear Barb,

> I found the article through a link at the web site you sent. I quote the

> article from it:

>

> http://www.epo.org/about-us/press/backgrounders/inventors2009.html

> Chronic myelogenous leukaemia (CML) was long-considered one of the

> deadliest forms of cancer, affecting both adults and children. But now with

> Glivec, a cancer fighting drug, CML has become much more treatable thanks to

> American oncologist Druker and Swiss medicinal chemist Jürg

> Zimmermann.

>

> In 1960, researchers discovered that CML was caused by an abnormally short

> chromosome and 13 years later it emerged that this was the result of

> chromosome swapping: therein lay the key to a cure. In 1990, researchers

> began looking for inhibitors of the fusion protein " BCR-ABL " , which causes

> the overproduction of white blood cells in the body. Scientists working for

> Swiss-based pharmaceutical company Novartis developed a compound designed to

> reduce BCR-ABL, and Jürg Zimmermann and his team set about improving the

> compound. In 1994, Novartis teamed up with oncologist Druker and set

> about refining the inhibitor. Today, the compound now known as Glivec is

> hailed as a wonder drug. Follow-up data shows that Glivec therapy helps

> stabilise the blood count of 98% of patients.

>

> Perhaps someone would come up with a novel idea for letting him know we

> appreciate the giant recognition if his dedication and work.

>

> FYI,

>

> Lottie

>

>

[Guest guest]

Hi Lottie,

Jurg is one of my heroes. Here is a utube of his acceptance speech.

Zavie

Zavie (age 70)

67 Shoreham Avenue

Ottawa, Canada, K2G 3X3

dxd AUG/99

INF OCT/99 to FEB/00, CHF

No meds FEB/00 to JAN/01

Gleevec since MAR/27/01 (400 mg)

CCR SEP/01. #102 in Zero Club

2.8 log reduction Sep/05

3.0 log reduction Jan/06

2.9 log reduction Feb/07

3.6 log reduction Apr/08

3.6 log reduction Sep/08

3.7 log reduction Jan/09

e-mail: zmiller@...

Tel: 613-726-1117

Fax: 309-296-0807

Cell: 613-282-0204

ID: zaviem

YM: zaviemiller

Skype: Zavie

_____

From: [mailto: ] On Behalf Of Lottie

Duthu

Sent: May 7, 2009 5:27 PM

CML

Subject: [ ] Dr. Druker Award

Dear Barb,

I found the article through a link at the web site you sent. I quote the

article from it:

http://www.epo.

<http://www.epo.org/about-us/press/backgrounders/inventors2009.html>

org/about-us/press/backgrounders/inventors2009.html

Chronic myelogenous leukaemia (CML) was long-considered one of the deadliest

forms of cancer, affecting both adults and children. But now with Glivec, a

cancer fighting drug, CML has become much more treatable thanks to American

oncologist Druker and Swiss medicinal chemist Jürg Zimmermann.

In 1960, researchers discovered that CML was caused by an abnormally short

chromosome and 13 years later it emerged that this was the result of

chromosome swapping: therein lay the key to a cure. In 1990, researchers

began looking for inhibitors of the fusion protein " BCR-ABL " , which causes

the overproduction of white blood cells in the body. Scientists working for

Swiss-based pharmaceutical company Novartis developed a compound designed to

reduce BCR-ABL, and Jürg Zimmermann and his team set about improving the

compound. In 1994, Novartis teamed up with oncologist Druker and set

about refining the inhibitor. Today, the compound now known as Glivec is

hailed as a wonder drug. Follow-up data shows that Glivec therapy helps

stabilise the blood count of 98% of patients.

Perhaps someone would come up with a novel idea for letting him know we

appreciate the giant recognition if his dedication and work.

FYI,

Lottie